Survey reveals lifestyle habits among diabetes patients
WOONSOCKET, R.I. CVS/pharmacy on Monday announced results of a survey examining various aspects of disease management and lifestyle for patients with diabetes. Of 3,242 respondents with diabetes, 32% reported they have been less vigilant about daily glucose testing due to cost, and as many as 24% of respondents said that cost has led them to be less conscientious about maintaining a proper diet.
Younger diabetics between the ages of 18 and 34 years cited significantly higher neglect of daily glucose testing (42%), proper diet (40%) and medication (29%) due to cost than older age groups. Challenges to maintaining a daily testing regimen also were cited more often by African-American (37%) and Latino (36%) respondents than by Caucasian respondents (30%).
"Given recent projections from the CDC that as many as 1-in-3 American adults could have diabetes by 2050, monitoring and maintaining healthy glucose levels is critical to prevent further complications from the disease and [to] avoid even more significant healthcare costs," stated Troyen Brennan, CVS Caremark chief medical officer. "We’ve established a number of programs to help patients manage their diabetes and the costs associated with the disease."
The survey revealed positive news about glucose monitoring with an A1c test. As many as 54% of respondents had an A1c test every three months, and 33% received an A1c test every six months. Among the 3,117 survey respondents who received an A1c test, 62% reported their most recently tested A1c level was within the range advised by their doctor.
MinuteClinic walk-in medical clinics inside select CVS/pharmacy stores are offering complimentary A1c tests to those with diabetes, in recognition of American Diabetes Month in November. The free tests, sponsored by Bayer Diabetes Care, are available while supplies last, the company stated.
Target launches anti-smoking campaign with American Cancer Society
MINNEAPOLIS — Target announced that it is launching a month-long anti-smoking campaign in connection with the American Cancer Society’s 2010 Great American Smokeout to support guests and team members in their efforts to quit smoking.
"Target is committed to helping our guests and team members reach their well-being goals, which may include quitting smoking, and we’re proud to work with the American Cancer Society for this year’s Great American Smokeout," said Dr. Joshua Riff, Target’s medical director. "As part of our focus on prevention, Target offers a variety of tools, tips and products for those who want to stop smoking and stay smoke-free. This campaign advances our prevention efforts and will ultimately lead to healthier communities."
The campaign will begin on Nov. 1 and will highlight Target’s assortment of stop-smoking aids and give greater visibility to Target Pharmacy and Target Clinic healthcare professionals, who can offer support, smoking-cessation materials and advice, the company reported. The campaign is anchored by in-store signing and informational brochures in all Target stores, as well as features in the weekly ad and at Target.com.
The American Cancer Society’s 35th annual Great American Smokeout takes place Nov. 18, and is designed to motivate and empower smokers with personalized tools, tips and support to help them quit for good.
GSK, Amicus to develop, commercialize Amigal
CRANBURY, N.J. British drug maker GlaxoSmithKline will work with U.S.-based Amicus Therapeutics to develop a drug for a rare genetic disease.
The two companies announced a deal to develop and commercialize Amigal (migalastat hydrochloride), a treatment for Fabry disease. Under the deal, GSK will pay Amicus $30 million upfront, as well as milestone payments of up to $170 million and royalties on future sales.
Fabry disease is a lysosomal storage disorder resulting from deficiencies of the enzyme alpha-galactosidase A. Lack of the enzyme results in buildup of a lipid called globotriaosylceramide, or GL-3, which is believed to cause the disease’s symptoms, such as pain, kidney failure and increased risk of heart attack and stroke. The disease affects 5,000 to 10,000 people worldwide.